Streetbeat News

Regulatory

RNAZ

TransCode Therapeutics has announced the publication of a U.S. patent application for 'Nanoparticles And Template Directed RIG-I Agonist Precursor Compositions And Uses Thereof For Cancer Therapy', marking a significant step in its cancer therapy research.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:08 pm

HRMY

Harmony Biosciences has been granted FDA Orphan Drug Designation for Pitolisant, a significant milestone that could enhance the company's market position and potentially lead to expedited development and approval processes for this drug.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:07 pm

OGN

Organon's HADLIMA, an FDA-approved biosimilar to HUMIRA, has been exclusively selected by the US Department of Veterans Affairs to replace HUMIRA on its National Formulary. This selection is for the treatment of various autoimmune or autoinflammatory conditions.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:04 pm

PEPG

PepGen Inc. has been granted FDA Fast Track Designation for its drug candidate PGN-EDODM1, aimed at treating Myotonic Dystrophy Type 1. This designation is expected to expedite the development and review process for the drug, potentially bringing it to market more quickly.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:03 pm

BFRI

Biofrontera has submitted a Form RW to the SEC, requesting the withdrawal of its previously filed registration statement on Form S-1. This move indicates a change in the company's plans regarding the securities initially intended to be offered to the public.

Portfolio Pulse from Charles Gross

February 20, 2024 | 1:00 pm

DFS

GFS

HD

INTC

NVDA

SSRM

WMT

US stocks are poised for a weaker open influenced by mixed retail earnings, with Home Depot reporting a sales decline and Walmart rising after acquiring VIZIO and posting solid results. Nvidia's upcoming earnings are highly anticipated, given its expected AI-driven growth. Last week's inflation reports led to a market pullback, ending a five-week winning streak for major indices. Discover Financial surged in premarket trading after an acquisition announcement, while GLOBALFOUNDRIES and Intel saw gains from government subsidies. SSR Mining's stock fell due to a temporary suspension of search and rescue activities.

Portfolio Pulse from Shanthi Rexaline

February 20, 2024 | 12:40 pm

META

Veteran trader Peter Brandt suspects his posts on X (formerly Twitter) are being censored due to his views on voting and COVID fraud, inspired by an interview with Mike Benz. Elon Musk has also accused Meta Platforms Inc. (META) of censorship, particularly around election integrity.

Portfolio Pulse from Benzinga Neuro

February 20, 2024 | 12:39 pm

CCM

Concord Medical Services Holdings Limited (CCM) received a non-compliance letter from the NYSE due to its American Depositary Share's trading price falling below the required minimum. The company must address this issue to regain compliance and avoid potential delisting.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:37 pm

RAPT

Rapt Therapeutics has been informed by the FDA of a clinical hold on its Phase 2B trial of Zelnecirnon in atopic dermatitis and its Phase 2A trial in asthma due to a serious adverse event of liver failure in one patient. Dosing and enrollment have been halted in both trials. The hold does not affect RAPT's oncology trial of tivumecirnon.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:35 pm

CMND

SPRC

Clearmind Medicine Inc. has submitted three international patent applications for psychedelic-based compounds, in collaboration with SciSparc Ltd., under the Patent Cooperation Treaty. These efforts are part of their ongoing partnership to develop therapies for central nervous system disorders.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:17 pm